Corp Symetryx Net Worth

The estimated Net Worth of Corp Symetryx is at least $892 Thousand dollars as of 7 September 2023. Corp Symetryx owns over 207,075 units of NeuBase Therapeutics stock worth over $178,766 and over the last few years Corp sold NBSE stock worth over $713,184.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Corp Symetryx NBSE stock SEC Form 4 insiders trading

Corp has made over 3 trades of the NeuBase Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently Corp sold 282,445 units of NBSE stock worth $375,652 on 14 September 2023.

The largest trade Corp's ever made was selling 282,445 units of NeuBase Therapeutics stock on 14 September 2023 worth over $375,652. On average, Corp trades about 183,532 units every 4 days since 2023. As of 7 September 2023 Corp still owns at least 472,926 units of NeuBase Therapeutics stock.

You can see the complete history of Corp Symetryx stock trades at the bottom of the page.

What's Corp Symetryx's mailing address?

Corp's mailing address filed with the SEC is 2828 BATHURST ST #400, , TORONTO, A6, M6B3A7.

Insiders trading at NeuBase Therapeutics

Over the last 5 years, insiders at NeuBase Therapeutics have traded over $713,184 worth of NeuBase Therapeutics stock and bought 177,514 units worth $548,788 . The most active insiders traders include Dov A Md Goldstein, Dietrich A Stephan, and Samuel Backenroth. On average, NeuBase Therapeutics executives and independent directors trade stock every 56 days with the average trade being worth of $37,929. The most recent stock trade was executed by Corp Symetryx on 14 September 2023, trading 282,445 units of NBSE stock currently worth $375,652.

What does NeuBase Therapeutics do?

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Complete history of Corp Symetryx stock trades at NeuBase Therapeutics

NeuBase Therapeutics executives and stock owners

NeuBase Therapeutics executives and other stock owners filed with the SEC include:

• Dietrich Stephan,
  President, Chief Executive Officer, Director
• Sam Backenroth,
  Chief Financial Officer, Treasurer, Secretary
• Eric Richman,
  Independent Director
• Franklyn Prendergast,
  Independent Director
• Diego Miralles,
  Independent Director
• Dov Goldstein,
  Independent Director
• Dr. Dietrich A. Stephan Ph.D.,
  Founder, Pres, CEO, Chairman & Interim CFO
• Dr. William Roland Mann MBA, Ph.D.,
  Chief Operating Officer
• Samuel Backenroth,
  CFO, Treasurer & Sec.
• Dan Ferry,
  IR Contact Officer
• William Mann,
  Chief Operating Officer
• Dr. Sandra Rojas-Caro M.D.,
  Chief Medical Officer
• Shannon McCarthy,
  Chief People Officer
• Alan Scrivner J.D.,
  VP of IP & Legal
• Dr. Anthony Rossomando Ph.D.,
  Chief Technology Officer
• Dr. Robert Zamboni Ph.D.,
  Chief of Preclinical Devel. & Member of Scientific Advisory Board
• Dr. Robert Friedlander M.D.,
  Consulting Chief Medical Officer
• Dr. Curt Bradshaw Ph.D.,
  Chief Scientific Officer
• Eric J Ende,
  Director
• Curt Bradshaw,
  Chief Scientific Officer
• Gerald J Mc Dougall,
  Director
• Kianoush Motesharei,
  See Remarks
• Todd P. Branning,
  Chief Financial Officer
• Corp Symetryx,
  10% owner
• Dietrich A Stephan,
  Founder and CEO